APOE4/4与阿尔茨海默氏症微质中损害的脂质滴有关
Michael S Haney1,2, Róbert Pálovics1,2, Christy Nicole Munson1,2
1Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.
Nature
|March 14, 2024
概括
阿尔茨海默病风险基因与质脂质代谢有关. 由β-粉样蛋白触发的脂质滴,促进tau病理和神经毒性,提供新的治疗点.
科学领域:
- 神经科学
- 遗传学
- 细胞生物学
背景情况:
- 阿尔茨海默病 (AD) 的遗传风险因素通常涉及脂质代谢基因在质细胞中高度表达.
- 质脂质代谢在阿尔茨海默症病理中的确切作用尚不清楚.
研究的目的:
- 研究微质脂质代谢与阿尔茨海默病病理之间的联系.
- 确定与AD相关的特定微质状态及其功能后果.
主要方法:
- 人类阿尔茨海默病大脑组织的单核RNA测序.
- 微质状态的分析,专注于像ACSL1这样的脂质滴相关酶.
- 在人体诱导多能干细胞衍生微质体暴露于纤维状Aβ的体外研究.
- 评估APOE基因型对脂质代谢和陶酸化的影响.
主要成果:
- 通过ACSL1表达特征的显著微质状态被确定,在APOE4/4AD患者中最为普遍.
- 纤维状Aβ诱导了ACSL1表达,甘油三合成和微细胞中的脂质滴积以一种依赖APOE的方式.
- 含有脂质滴的微细胞释放了诱导酸化和神经毒性的因素,也依赖于APOE.
结论:
- 微质脂肪液滴积累与阿尔茨海默病的遗传风险因素有关.
- APOE基因型显著影响微质脂质代谢和随后的神经毒性作用.
- 这些发现强调微质脂质代谢是阿尔茨海默病的潜在治疗点.
相关概念视频
01:26Alzheimer's Disease: Overview
475
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
475
01:22Alzheimer's Disease: Treatment
186
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
186